AstraZeneca AZN announced positive top-line data from the phase III Bax24 study evaluating the safety, tolerability and ...

Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic ...

More than half of U.S. adults with uncontrolled hypertension are unaware they have hypertension in the first place, according to a recent study in JAMA Network Open. Furthermore, more than two-thirds ...

AstraZeneca's Baxdrostat cut 24-hour systolic blood pressure in a Phase 3 trial, showing promise for treatment-resistant ...

The World Health Organization (WHO) today released its second Global hypertension report, showing that 1.4 billion people ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In over 3,000 adults, over half were unaware they had ...

Resistant hypertension affects 1 in 10 with high BP, persisting despite multiple medications. Experts warn it needs early ...

Findings showed treatment with lorundrostat resulted in statistically significant reductions in systolic blood pressure compared with placebo. Topline data were announced from a phase 3 trial ...

The World Health Organisation (WHO) released its second Global Hypertension Report, showing that 1.4 billion people lived ...

AstraZeneca's experimental drug baxdrostat significantly lowered blood pressure in a 24-hour window during a late-stage trial ...

“There is no current alternative to treating resistant hypertension or poorly controlled hypertension with medical therapy, except for renal denervation,” said Hussein Abu Daya, M.D., an assistant ...

The alarming statistics highlight the urgent need for increased awareness and proactive measures to address this growing ...